Bronchial Leiomyoma Market Report Size and Forecast to 2027

Posted by Apeksha on July 2nd, 2021

Bronchial Leiomyoma Market Research Report: By Site (Bronchi, Trachea), Diagnosis (Imaging, Blood Sampling, Biopsy), Treatment (Surgery, Bronchoscopy), End User (Hospitals & Clinics, Academic Institutes, Research Organization) - Global Forecast till 2027

Market Highlights

Bronchial Leiomyoma Market Report affects the lower respiratory tract tissues including bronchi, trachea, besides others and is a rare type of lung cancer. A majority of the cases of bronchial leiomyoma are reported to arise from the smooth muscle tissue lining of the bronchi. Being attached to the sides of the bronchi, the bronchial leiomyoma tumor grows as a solitary tumor.  In 2017, according to the American Cancer Society, about 222,500 new cases of lung cancer are reported which is likely to lead 155,870 deaths. With such an increasing prevalence of the lung cancer, the cases of the bronchial leiomyoma are estimated to be increasing, which is likely to drive the market growth during the forecast period, 2017-2023. 

Regional Analysis

The Americas dominate the global market owing to a well-developed healthcare sector. Apart from this, increasing number of patients, increasing healthcare expenditure have boosted the growth of the market in the Americas. According to the Centers for Disease Control and Prevention in 2015, the U.S. total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which was USD 3.2 trillion.

Key Players

Hoffmann-La Roche Ltd (Europe), AstraZeneca (Europe), Eli Lilly and Company. (U.S.), Sanofi (Europe), Pfizer Inc. (U.S.), GlaxoSmithKline Plc. (U.S.), ArQule. (U.S.), Boehringer Ingelheim GmbH (Europe), and others.

Browse Detailed TOC with COVID-19 Impact Analysis at:


Akash Anand

Market Research Future

+1 646 845 9312


Like it? Share it!


About the Author

Joined: April 9th, 2018
Articles Posted: 489

More by this author